Despite limited number of studies, oxysterols are known to contribute to the progression of nonalcoholic steatohepatitis (NASH) by affecting lipid/cholesterol metabolism and elevating proinflammatory and profibrotic processes. Accordingly, we used a high cholesterol-mediated in vivo NASH model and aimed to determine alterations in fatty acid content and oxysterol levels together with their effects on cholesterol/lipid metabolism during the progression of the disease. We further investigated the beneficial role of α-tocopherol. To this end, in our hypercholesterolemic rabbit model, we determined fatty acid profile by GC-MS while 25-, 27-, 4β-, 7α, and 24(S)-Hydroxycholesterol levels by means of LC-MS/MS. Additionally, lipid (SREBP-1c, PPARα, PPARγ) and cholesterol metabolism-related proteins (LXRα, SREBP2 and ABCA1) were determined by immunoblotting. In conclusion, the present findings provide a complete analysis of the hepatic alterations in lipid and oxysterol profiles mediated by a high-cholesterol diet. In addition, this study explains the protective effect of α-tocopherol on lipogenesis and oxysterol production in hypercholesterolemia-induced NASH. We believe that present study will guide to novel theories in the progression and therapeutic targeting of fatty liver diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10715762.2024.2421173 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protective effect of alpha-tocopherol on lipogenesis and oxysterol production in hypercholesterolemia-induced nonalcoholic steatohepatitis.
Free Radic Res
October 2024
Department of Biochemistry, Faculty of Medicine, Uskudar University, Istanbul, Turkey.
Despite limited number of studies, oxysterols are known to contribute to the progression of nonalcoholic steatohepatitis (NASH) by affecting lipid/cholesterol metabolism and elevating proinflammatory and profibrotic processes. Accordingly, we used a high cholesterol-mediated in vivo NASH model and aimed to determine alterations in fatty acid content and oxysterol levels together with their effects on cholesterol/lipid metabolism during the progression of the disease. We further investigated the beneficial role of α-tocopherol.
View Article and Find Full Text PDFLeonurine Inhibits Hepatic Lipid Synthesis to Ameliorate NAFLD via the ADRA1a/AMPK/SCD1 Axis.
Int J Mol Sci
October 2024
School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China.
Article Synopsis
- Leonurine, a compound derived from the Lamiaceae plant, shows potential benefits in treating nonalcoholic fatty liver disease (NAFLD) due to its anti-oxidative, anti-apoptotic, and metabolic regulation properties, though its exact mechanisms are not fully understood.
- In a study involving mice, different groups were treated with leonurine and other treatments to observe changes in liver health after a high-fat high-sugar diet, revealing that leonurine positively influenced lipid metabolism-related genes.
- Further analysis indicated that leonurine may lower lipid levels by activating the AMPK signaling pathway and affecting lipid molecules, specifically through the ADRA1a/AMPK/SCD1 axis, thus improving liver lipid
Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
Hepatology
July 2024
Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- The study investigates the role of IL22RA1 in regulating lipid metabolism in the liver, linking it to conditions like NAFLD (non-alcoholic fatty liver disease).
- It shows that IL22RA1 is downregulated in unhealthy liver conditions, leading to increased fat accumulation and insulin resistance in liver-specific knockout mice.
- The research concludes that IL22RA1 helps maintain lipid balance in the liver, and its absence results in harmful lipid accumulation through a specific molecular pathway involving oxysterols.
Regulation and targeting of SREBP-1 in hepatocellular carcinoma.
Cancer Metastasis Rev
June 2024
Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020, Innsbruck, Austria.
Hepatocellular carcinoma (HCC) is an increasing burden on global public health and is associated with enhanced lipogenesis, fatty acid uptake, and lipid metabolic reprogramming. De novo lipogenesis is under the control of the transcription factor sterol regulatory element-binding protein 1 (SREBP-1) and essentially contributes to HCC progression. Here, we summarize the current knowledge on the regulation of SREBP-1 isoforms in HCC based on cellular, animal, and clinical data.
View Article and Find Full Text PDFKnockout of secretin ameliorates biliary and liver phenotypes during alcohol-induced hepatotoxicity.
Cell Biosci
January 2023
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Alcohol-related liver disease (ALD) is characterized by ductular reaction (DR), liver inflammation, steatosis, fibrosis, and cirrhosis. The secretin (Sct)/secretin receptor (SR) axis (expressed only by cholangiocytes) regulates liver phenotypes in cholestasis. We evaluated the role of Sct signaling on ALD phenotypes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!